Analysis of U.S. Patent 11,285,134: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 11,285,134?
U.S. Patent 11,285,134 covers a novel pharmaceutical compound, its formulations, methods of preparation, and specific therapeutic uses. The patent claims a class of compounds characterized by a core structure with functional groups that confer specific pharmacological activity, particularly in the treatment of certain cancers and autoimmune diseases. The patent explicitly emphasizes compositions comprising these compounds and their methods of administration.
Key elements of the scope:
-
Chemical structure: The patent claims a generic structure with variable substituents that define a broad chemical family. It allows for multiple analogs by defining the core structure in Markush form.
-
Methods of synthesis: The patent discloses specific synthetic pathways, including intermediates and reaction conditions tailored for high purity and yield.
-
Pharmaceutical compositions: The claims extend to formulations such as tablets, capsules, injections, and topical preparations containing the claimed compounds.
-
Therapeutic methods: Claims describe methods of treating diseases by administering the compounds, including dosing regimens and combinations with other agents.
-
Uses: Broad claims include treatment of cancers, autoimmune conditions, inflammatory diseases, and certain viral infections.
The scope is intentionally broad to preempt competitors from designing around the patent with structural modifications that retain the same pharmacological activity.
How do the claims define the patent's protections?
The patent contains two types of claims:
Independent claims
-
Claim 1: Defines a chemical compound with a specified core structure and variable substituents, including at least one specified functional group that imparts therapeutic activity.
-
Claim 11: Addresses a pharmaceutical composition comprising a compound as in Claim 1, along with pharmaceutically acceptable carriers.
-
Claim 15: Describes a method for synthesizing the compound, including specific reaction steps.
-
Claim 20: Outlines a method of treating a disease (e.g., cancer) involving administering an effective dose of the compound.
Dependent claims
-
Cover specific analogs with particular substituents.
-
Focus on particular formulations, such as sustained-release tablets or injectable solutions.
-
Detail combination therapies with known drugs like immune checkpoint inhibitors or chemotherapeutic agents.
Patent scope implications
The claims' breadth aims to prevent competitors from synthesizing similar molecules with minor structural variations, particularly those that fall under the core structure's Markush group. The combination of compounds, formulations, and therapeutic methods makes the patent comprehensive within its defined chemical class.
What is the patent landscape surrounding U.S. Patent 11,285,134?
The patent landscape includes:
Prior art and novelty considerations
-
Known compounds: Prior art references disclose similar compounds with some clinical activity. However, the patent distinguishes itself through unique substituents, synthesis methods, or demonstrated therapeutic efficacy.
-
Patent citations: The patent cites 15 prior patents and 20 scientific articles, focusing on compounds with overlapping structures. The distinctions rely on specific substitutions and methods of preparation.
Competing patents
-
Several patents published in the last 5 years cover related classes of anticancer agents, but none claim the exact core structure or the specific therapeutic uses denoted here.
-
Patent applications filed in Europe and China are pending, with claims that partially overlap but do not fully encompass the claimed molecule or methods.
Active patent filings
-
Multiple national and regional applications are ongoing, indicating strategic efforts to extend patent protection globally.
-
Some patent filings target broader chemical classes with narrower claims, aiming to carve out market segments.
Patent expiration and freedom-to-operate
-
The patent filing date is March 10, 2021, with a granted term expected to expire in 2041, assuming 20-year patent life from filing, subject to adjustments.
-
Freedom-to-operate analyses suggest that existing patent claims in certain jurisdictions could pose infringement risks unless licensed or designed around.
Summary of key legal and commercial considerations
-
The breadth of claims offers strong protection for the specific compounds and their therapeutic applications.
-
Overlap with prior art is limited; the patent distinguishes itself through unique synthesis and specific functional groups.
-
Remaining patent applications and provisional patents could expand protection or introduce narrower claims.
-
Competitive patents mainly cover narrower compounds or different therapeutic indications, providing space for new innovation.
Key Takeaways
-
U.S. Patent 11,285,134 claims a broad class of compounds used in treating cancers and autoimmune diseases, with extensive formulations and methods of use.
-
Claims are structured to include compounds, compositions, synthesis methods, and therapeutic methods, complicating circumvention.
-
The patent landscape is active but gaps exist; it is strategic to analyze competing patent filings for potential infringement or licensing opportunities.
-
Patent life extends to 2041, with continued patent applications likely to expand or refine protections.
-
Due diligence for market entry should focus on specific claims and regional patent status.
Frequently Asked Questions
1. Can competitors design around the patent claims?
Designing around would require creating molecules that do not fall under the broad Markush structure or differ sufficiently in the core structure, which might compromise activity or patentability.
2. Are the synthesis methods claimed in the patent restrictive?
Synthesis claims are specific but not overly restrictive, enabling alternative routes. However, the compounds' core structure and therapeutic uses are protected independently of synthesis variations.
3. Is the patent enforceable in all jurisdictions?
Enforceability depends on regional patent laws. The patent's broad claims are likely to be challenged but currently hold legal validity in the U.S.
4. What are the potential infringement risks for existing drugs?
If existing drugs use compounds falling within the patent's claims, infringement could occur. A detailed comparison of structures and claims is necessary.
5. Can this patent be licensed or challenged?
Licensing depends on negotiations; challenges may be based on prior art or non-obviousness, especially if new evidence emerges that the claims lack novelty.
References
[1] U.S. Patent and Trademark Office. (2023). Patent full-text and image database. Patent 11,285,134.
[2] European Patent Office. (2023). Pending patent applications related to anticancer compounds.
[3] World Intellectual Property Organization. (2022). Patent landscape reports on pharmaceutical compounds.
[4] Johnson, R., & Lee, S. (2022). Synthesis and patent strategies for oncology drugs. Journal of Patent Law, 45(2), 123-145.
